<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26694" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Paroxysmal Atrial Fibrillation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ludhwani</surname>
            <given-names>Dipesh</given-names>
          </name>
          <aff>Rosalind Franklin University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wieters</surname>
            <given-names>Jerald S.</given-names>
          </name>
          <aff>Baylor Scott &#x00026; White</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Dipesh Ludhwani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jerald Wieters declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26694.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Atrial fibrillation (AF) causes an irregularly irregular heart rhythm. AF is the most common sustained arrhythmia characterized by disorganized, rapid, and irregular atrial activation leading to an irregular ventricular response. As a result of the above effects, atrial contractility is lost causing an inability to completely empty blood from atrial appendage leading to the risk of clot formation and subsequent thromboembolic events. AF can be classified into many subtypes depending on its characteristics and duration. This activity illustrates the evaluation and treatment of atrial fibrillation and reviews the role of the interprofessional team in managing those with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe presenting features of atrial fibrillation.</p></list-item><list-item><p>Review causes of atrial fibrillation.</p></list-item><list-item><p>Summarize management strategies for atrial fibrillation.</p></list-item><list-item><p>Outline interprofessional team strategies to improve care coordination and communication to enhance outcomes for patients affected by atrial fibrillation.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26694&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26694">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26694.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A normal heartbeat consists of a sequential contraction of atria followed by ventricles in a series of cardiac cycle events. The succession of 3 such regular heartbeats displaying identical waveform leads to a steady rhythm. The stimulus for each heartbeat commonly originates from the sinus node in the right atria, hence the name sinus rhythm. Abnormal heart rate or rhythm, which is not physiologically justified, is known as arrhythmia. Arrhythmias are almost always pathological except sinus arrhythmia, which is physiological. As the name suggests, sinus arrhythmia originates from the sinus node, but the regularity between each heartbeat varies with inspiration and expiration. All pathological arrhythmia can be further classified based on heart rate into tachyarrhythmia (fast), bradyarrhythmia (slow), or tachy-brady (fast-slow) arrhythmia.</p>
        <p>All tachyarrhythmia originating above the ventricles, including atria and atrioventricular node (AV node), are grouped under supraventricular tachycardia (SVT).<xref ref-type="bibr" rid="article-26694.r1">[1]</xref>&#x000a0;Examples of SVT include atrial flutter, atrial fibrillation (AF), atrioventricular nodal reentrant tachycardia (AVNRT), also known as paroxysmal supraventricular tachycardia (PSVT), atrioventricular reentrant tachycardia (AVRT), and multifocal atrial tachycardia (MAT). Atrial fibrillation (AF) is a subtype of SVT that causes an irregularly irregular heart rhythm. AF is the most common sustained arrhythmia characterized by disorganized, rapid,&#x000a0;and irregular atrial activation leading to an irregular ventricular response. As a result of the above effects, atrial contractility is lost, causing an inability to completely empty blood from the atrial appendage leading to the risk of clot formation and subsequent thromboembolic events. Ventricular response to atrial activation depends on the conduction properties of the AV node. Typically&#x000a0;the heart rate varies from 120 to 160 beats per minute; however, heart rate as fast as 200 beats per minute can be seen.</p>
        <p>The American Heart Association and American College of Cardiology further classified AF as follows:<xref ref-type="bibr" rid="article-26694.r2">[2]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Paroxysmal AF: intermittent&#x000a0;in nature, terminating spontaneously or within 7 days of treatment.</p>
          </list-item>
          <list-item>
            <p>Persistent AF: Failure to terminate in 7 days</p>
          </list-item>
          <list-item>
            <p>Long-lasting AF: AF lasting for more than 12 months</p>
          </list-item>
          <list-item>
            <p>Permanent AF: Persistent AF where rhythm strategy is no longer pursued</p>
          </list-item>
        </list>
        <p>
<bold>Other Types of AF</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Lone AF: Lone AF is used to describe patients younger than 60 years with no other concomitant heart disease and structurally normal heart on an echocardiogram.</p>
          </list-item>
          <list-item>
            <p>Non-Valvular AF: Defines whether AF is related to valvular disease, replacement, or repair. It is much more difficult to convert valvular AF into sinus rhythm.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26694.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Atrial fibrillation is commonly associated with conditions that alter the structure of the heart. Important causes and risk factors for AF are as follows:</p>
        <p>
<bold>Cardiac Causes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertensive heart disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Coronary artery disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Valvular heart disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Heart failure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Congenital heart disease</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Infiltrative cardiac disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sick sinus syndrome</p>
          </list-item>
          <list-item>
            <p>Pre-excitation syndrome</p>
          </list-item>
        </list>
        <p>
<bold>Non-Cardiac Causes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic lung disease&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pulmonary embolism</p>
          </list-item>
          <list-item>
            <p>Electrolyte abnormalities</p>
          </list-item>
          <list-item>
            <p>Acute infections&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Thyroid disorders</p>
          </list-item>
          <list-item>
            <p>Pheochromocytoma</p>
          </list-item>
          <list-item>
            <p>Hypothermia</p>
          </list-item>
          <list-item>
            <p>Post-surgical (seen in 35% to 50% of patients post coronary artery bypass graft)<xref ref-type="bibr" rid="article-26694.r3">[3]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Risk Factors</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Age-related fibrosis</p>
          </list-item>
          <list-item>
            <p>Diabetes</p>
          </list-item>
          <list-item>
            <p>Obesity&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Metabolic syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Obstructive sleep apnea</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>High-intensity exercise</p>
          </list-item>
          <list-item>
            <p>Genetic factors</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26694.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Researchers of a 2010&#x000a0;study systematically reviewed 184 population-based studies for AF and estimated that approximately 33.5 million individuals in the world have AF.<xref ref-type="bibr" rid="article-26694.r4">[4]</xref>&#x000a0;AF prevalence has gradually increased over the last few decades. Based&#x000a0;on the Centers for Disease Control and Prevention (CDC) estimate in 2017, 2.6 to 6.1 million people in the United States have AF. Further, the prevalence increases with age, and approximately 9% of all adults aged greater than 80 have AF.<xref ref-type="bibr" rid="article-26694.r5">[5]</xref><xref ref-type="bibr" rid="article-26694.r6">[6]</xref>&#x000a0;Europe has a higher prevalence of AF compared to the&#x000a0;United States. Similar to the prevalence, the incidence of AF increases with age. In all age groups, males are more commonly affected than females. Despite a high prevalence of risk factors, African Americans tend to&#x000a0;have lower AF incidence compared to Caucasians.<xref ref-type="bibr" rid="article-26694.r6">[6]</xref></p>
      </sec>
      <sec id="article-26694.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The underlying mechanism for AF is related to a complex interaction between triggers and substrate. Triggers are responsible for initiating the event (arrhythmia), and substrate will maintain that arrhythmia. Triggers arise when the action potential induces after-depolarization that is strong enough to overcome recovering repolarization.<xref ref-type="bibr" rid="article-26694.r7">[7]</xref>&#x000a0;This after-depolarization can cause extra systole but cannot maintain persistent arrhythmia. Impulses from such extrasystoles, however, are discharged at high frequency. When these impulses encounter the myocardium with variable excitability or refractoriness, it gives rise to functional electrical blocks. Re-entry circuits arise, which in turn&#x000a0;gives rise to new impulse waves generating additional re-entry circuits that help maintain persistent arrhythmia to overcome such blocks.<xref ref-type="bibr" rid="article-26694.r8">[8]</xref></p>
        <p>The most common site for ectopic foci and trigger origin is the left atrial muscular sleeve extending into the pulmonary vein. Myocardial cells in this region display a shorter refractory period compared to surrounding myocardium and patients without AF.&#x000a0;Pulmonary vein isolation (PVI) performed during catheter ablation for AF aims to isolate this region from the surrounding myocardium dissipating further development of AF. Occasionally, AF can be triggered by other arrhythmias such as AVRT/ Atrial flutter and even premature atrial contractions (PACs). Atrial remodeling arising from electrical, structural, and autonomic changes of the myocardium promotes both trigger and substrate. These changes lead to altered sympathovagal activity, a shorter refractory period, and increased&#x000a0;atrial&#x000a0;inducibility propagating AF.<xref ref-type="bibr" rid="article-26694.r9">[9]</xref><xref ref-type="bibr" rid="article-26694.r10">[10]</xref>&#x000a0;Inflammatory and oxidative changes&#x000a0;are also noted at the molecular level, which can&#x000a0;be correlated with the high C-reactive protein (CRP) level.&#x000a0;AF can cause hemodynamic and electrophysiological changes causing increased susceptibility to new episodes of AF.<xref ref-type="bibr" rid="article-26694.r11">[11]</xref></p>
      </sec>
      <sec id="article-26694.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical presentation for AF can range from asymptomatic incidental findings on an electrocardiogram (ECG) to a catastrophic stroke with an undiagnosed underlying irregular rhythm. More commonly, symptoms are similar to other arrhythmias like palpitations, dyspnea at rest or exertion, angina-like symptoms, fatigue or decreased exercise tolerance, lightheadedness, diaphoresis, dizziness, and pre-sync and syncope. AF can also masquerade as symptoms of heart failure exacerbation like weight gain, pedal edema, and pulmonary congestion.</p>
        <p>All patients presenting with the above symptoms should have a detailed history, including&#x000a0;past&#x000a0;medical/cardiac history.&#x000a0;On physical examination, patients should be examined for an irregularly irregular pulse, signs of heart failure like jugular vein distension (JVD), pedal edema, and lung crackles. In valvular AF, mitral stenosis/regurgitation murmur can be heard. A history of&#x000a0;prior investigation of underlying causes, anticoagulation choices,&#x000a0;and previously attempted methods for rate/rhythm control is important.</p>
      </sec>
      <sec id="article-26694.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>As mentioned above, all patients being evaluated for AF should have a detailed history and physical exam. Diagnosis of AF is based on characteristic ECG findings.&#x000a0;ECG findings as seen in patients with AF:</p>
        <list list-type="bullet">
          <list-item>
            <p>The absence of distinct &#x0201c;P&#x0201d; waves</p>
          </list-item>
          <list-item>
            <p>Irregularly irregular R-R interval.</p>
          </list-item>
          <list-item>
            <p>Narrow QRS complex tachycardia, typically with the heart rate between 110 and 160; QRS duration fewer than 0.12 seconds unless accompanied by pre-existing bundle block, aberrant conduction, or accessory pathway</p>
          </list-item>
          <list-item>
            <p>Fibrillatory waves may be present, which can mimic &#x0201c;P&#x0201d; waves.</p>
          </list-item>
        </list>
        <p>Ashman phenomenon: QRS morphology is usually unaffected in AF. However, in cases with aberrant ventricular conduction, bundle branch block can occur due to an abrupt change in length&#x000a0;of the cardiac cycle. These aberrantly conducted beats are usually of right bundle branch block morphology.<xref ref-type="bibr" rid="article-26694.r12">[12]</xref></p>
        <p>Further evaluation should include a workup to identify the cause of AF. Patients should be tested for electrolyte abnormalities, endocrine&#x000a0;disorders&#x000a0;(specifically hyperthyroid), drug-induced causes, infections, drug or chemical withdrawal, and echocardiography to check for structural heart disease. In patients presenting with ischemic stroke and with no prior history of AF, 72-hour Holter monitoring improves the detection rate of silent paroxysmal AF.<xref ref-type="bibr" rid="article-26694.r13">[13]</xref></p>
      </sec>
      <sec id="article-26694.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment strategy involves antithrombotic therapy and selection between rate or rhythm control. Previous randomized studies such as Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) and&#x000a0;Rate Control versus&#x000a0;Electrical Cardioversion for Persistent Atrial Fibrillation (RACE)&#x000a0;have shown no superiority with one compared to other.<xref ref-type="bibr" rid="article-26694.r14">[14]</xref><xref ref-type="bibr" rid="article-26694.r15">[15]</xref><xref ref-type="bibr" rid="article-26694.r16">[16]</xref></p>
        <p>
<bold>Antithrombotic Therapy</bold>
</p>
        <p>AF is associated with a 5-fold increased risk of stroke. Whether all patients with AF need anticoagulation regardless of risk factor status is debatable. The embolic risk in patients with AF is estimated using the CHA2DS2-VASc risk model (congestive heart failure, hypertension, age, diabetes mellitus, prior stroke, vascular disease, sex).<xref ref-type="bibr" rid="article-26694.r17">[17]</xref>&#x000a0;A higher CHA2DS2-VASc score correlates with a higher risk of ischemic stroke per year. The risk of AF-related ischemic strokes increases from 1.3% to 2.2% as the CHA2DS2-VASc score increases from 1 to 2. Benefits with antithrombotic therapy are well documented in moderate to high-risk AF patients (CHA2DS2-VASc score equal to 2). However,&#x000a0;its use in low-risk patients (CHA2DS2-VASc score less than 2) is often controversial as benefits are not well-defined.<xref ref-type="bibr" rid="article-26694.r18">[18]</xref><xref ref-type="bibr" rid="article-26694.r19">[19]</xref></p>
        <p>The benefits of anticoagulation should be balanced against the risk of bleeding. HAS-BLED scoring system (hypertension, abnormal renal/liver function, stroke, bleeding history, labile international normalized ratio, elderly, drugs/alcohol) is widely used to estimate the risk of bleeding from anticoagulation. The HAS-BLED score equal to 3 is associated with an increased risk of bleeding. Once the patient&#x02019;s individualized stroke risk is determined, the selection of antithrombotic therapy varies from one patient to another. Compared to warfarin-aspirin, monotherapy is not recommended for primary stroke prevention in patients with AF.<xref ref-type="bibr" rid="article-26694.r20">[20]</xref>&#x000a0;Warfarin therapy needs constant monitoring with International Normalized Ratio (INR) to maintain the therapeutic range between 2.0 to 3.0, which usually requires bridging with heparin while initiating therapy. Several newer non-vitamin K antagonist oral anticoagulants (NOAC) have a shorter duration of action, not requiring heparin bridging. Trials such as RE-LY, ROCKET-AF, ARISTOTLE have shown similar effectiveness and decreased intracranial bleeding risk with NOACs (apixaban, rivaroxaban, dabigatran, edoxaban) when compared head-to-head with warfarin.<xref ref-type="bibr" rid="article-26694.r21">[21]</xref><xref ref-type="bibr" rid="article-26694.r22">[22]</xref><xref ref-type="bibr" rid="article-26694.r23">[23]</xref>&#x000a0;NOACs, do not require routine INR testing, but they have challenges with access to rapid reversal agents. This is an area of rapid development. In patients with prosthetic heart valves and valvular AF, warfarin remains the preferred drug of choice. The selection of antithrombotic agents should be based on account of risk factors, cost tolerability, patient preference, and potential drug interaction.</p>
        <p>
<bold>Rate Control</bold>
</p>
        <p>Rate control is the preferred strategy for all asymptomatic AF patients. Guidelines on target heart rate in patients selected for rate control are lacking. A previously conducted randomized trial (RACE II) to assess heart rate goal in patients with AF showed no outcome difference between lenient and strict heart rate control; however, sufficient evidence to assess the impact on all-cause mortality was lacking. Physicians usually attempt to control heart rate control with agents such as beta-blockers (metoprolol, esmolol, propranolol), nondihydropyridine calcium-channel blockers (verapamil, diltiazem), or digoxin. All 3 classes of drugs are given intravenously (IV) for acute rate control and can be switched to oral therapy for chronic management. In patients with chronic heart failure with reduced ejection fraction, carvedilol therapy has shown significant improvement in left ventricular ejection fraction. Due to the negative inotropic properties of calcium channel blockers, physicians do not use these not preferred in such patients. Digoxin is usually reserved for patients who do not achieve rate control with beta-blockers or calcium channel blockers alone. Amiodarone can be used as second-line therapy when treatment with other agents has failed.<xref ref-type="bibr" rid="article-26694.r23">[23]</xref>&#x000a0;In patients refractory to medical therapy, AV node ablation with a permanent pacemaker placement can effectively&#x000a0;control and regularize ventricular heart rate.&#x000a0;Low doses of magnesium have shown synergistic effects on rate control.<xref ref-type="bibr" rid="article-26694.r24">[24]</xref></p>
        <p>
<bold>Rhythm Control</bold>
</p>
        <p>The decision to achieve rhythm control either with pharmacological or non-pharmacological (electric) methods is based on the presence or absence of symptoms, age, and other comorbidities. Rhythm control with pharmacological therapy alone is associated with increased side effects and a lower success rate.<xref ref-type="bibr" rid="article-26694.r25">[25]</xref>&#x000a0;The risk and side effects of specific antiarrhythmics should be considered before drug selection. Class I sodium channel blocking agents (flecainide, propafenone, disopyramide) have negative, inotropic action, and healthcare professionals&#x000a0;should avoid these agents in patients with a history of coronary artery disease or heart failure. Class III agents (sotalol, dofetilide) have a 3% risk of causing QT prolongation and should be initiated while in hospital. Other class III antiarrhythmic like amiodarone has greater long-term efficacy; however, over 20% of patients develop toxicities during long-term therapy. Drug therapy is most commonly used in adjunction to direct current cardioversion (DCCV). DCCV is associated with a high immediate success rate.<xref ref-type="bibr" rid="article-26694.r26">[26]</xref>&#x000a0;It is commonly performed in patients with hemodynamic compromise and patients with new-onset AF (fewer than 48 hours) who are candidates for rhythm control. Patients undergoing DCCV should have preexisting atrial thrombus ruled out with either transthoracic or transesophageal echocardiography. Anticoagulation with warfarin 3 weeks prior and 4 weeks after DCCV&#x000a0;is&#x000a0;recommended for patients when the duration of AF is greater than 48 hours. The risk of AF recurrence post-DCCV is high and can be reduced with the use of antiarrhythmic medications. In patients with contraindication to antiarrhythmic therapy, catheter or surgical ablation can be attempted. Ablation is performed with the aim to electrically isolate the pulmonary vein (trigger foci) from the rest of the atrial myocardium. Catheter ablation is associated with high success rates (70%). No significant difference in AF burden was noted between catheter ablation and oral antiarrhythmic therapy; however, overall symptoms and quality of life were significantly better in patients receiving ablation.<xref ref-type="bibr" rid="article-26694.r27">[27]</xref>&#x000a0;A surgical ablation is a reasonable option for AF patients undergoing cardiac surgery for other indications. The decision to perform catheter ablation or antiarrhythmic medications used to maintain sinus rhythm is guided by patient symptoms and the risk/benefits of each therapy.</p>
      </sec>
      <sec id="article-26694.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="order">
          <list-item>
            <p>Sinus tachycardia</p>
          </list-item>
          <list-item>
            <p>Atrial flutter</p>
          </list-item>
          <list-item>
            <p>Atrial flutter with variable block</p>
          </list-item>
          <list-item>
            <p>Atrial tachycardia (AT)</p>
          </list-item>
          <list-item>
            <p>Multifocal atrial&#x000a0;tachycardia (MAT)</p>
          </list-item>
          <list-item>
            <p>Wolff-Parkinson-White syndrome (WPW)</p>
          </list-item>
          <list-item>
            <p>Atrioventricular nodal reentry tachycardia (AVNRT)</p>
          </list-item>
          <list-item>
            <p>Atrioventricular reentry tachycardia (AVRT)</p>
          </list-item>
          <list-item>
            <p>Junctional ectopic tachycardia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26694.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>AF is associated with increased cardiovascular mortality.<xref ref-type="bibr" rid="article-26694.r14">[14]</xref>&#x000a0;Anticoagulation in all patients with&#x000a0;a CHA2DS2-VASc score equal to&#x000a0;2 has shown an improved prognosis.&#x000a0;Patients not on anticoagulation are at high risk for thromboembolic events. Fifty-five percent of AF patients are not on antithrombotic therapy, which accounts for over 50,000 strokes annually.<xref ref-type="bibr" rid="article-26694.r28">[28]</xref>&#x000a0;The prognosis for AF-related stroke is worse compared to non-AF-related cerebrovascular events. Patients with heart failure are at increased risk of developing AF-related complications. Elevated high sensitivity C-reactive protein (hs-CRP) and troponins have been implicated with adverse outcomes in AF patients.<xref ref-type="bibr" rid="article-26694.r29">[29]</xref></p>
      </sec>
      <sec id="article-26694.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications associated with AF include the following:<xref ref-type="bibr" rid="article-26694.r30">[30]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Thromboembolism including stroke</p>
          </list-item>
          <list-item>
            <p>New-onset heart failure or worsening of existing heart failure</p>
          </list-item>
          <list-item>
            <p>Acute myocardial infarction</p>
          </list-item>
          <list-item>
            <p>Hemodynamic instability leading to cardiogenic shock</p>
          </list-item>
          <list-item>
            <p>Sudden death from Wolff-Parkinson-White syndrome</p>
          </list-item>
          <list-item>
            <p>Tachycardia-induced cardiomyopathy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26694.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Atrial fibrillation is the&#x000a0;most common cardiac arrhythmia associated with an increased risk of ischemic stroke. Practitioners should educate all patients about the risk and benefits of anticoagulation. It is important to explain to patients that the risk of stroke increases exponentially each year without anticoagulation. Clinicians should offer the patient choices among various anticoagulation&#x000a0;options and treatment strategies to improve adherence and decrease the side effect profile.&#x000a0;Stress should be laid on regular INR testing to maintain a therapeutic&#x000a0;range while taking warfarin. Furthermore, physicians&#x000a0;should counsel the patient about red-flag signs such as shortness of breath, palpitations, fatigue, and weight gain. Patients should learn to reduce AF recurrence non-pharmacologically by cutting down on caffeine&#x000a0;intake, avoiding alcohol, and exercising regularly.</p>
      </sec>
      <sec id="article-26694.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>AF is a huge financial burden on health care. Therefore, managing AF requires an interprofessional approach with close involvement of various health care professionals such as primary&#x000a0;care physicians, cardiologists, electrophysiologists, neurologists, surgeons, pharmacists, and nursing staff.</p>
        <p>Ensuring guideline-directed treatment of AF is pivotal in improving overall outcomes and reducing health care costs. Nurse-led, guideline-based clinics supported by appropriate&#x000a0;software and cardiologists have shown superior results in cardiovascular mortality and hospitalizations.<xref ref-type="bibr" rid="article-26694.r31">[31]</xref> (Level I). Outpatient specialty AF clinics have shown better outcomes in AF-related hospitalizations and quality of life compared to usual care clinics.<xref ref-type="bibr" rid="article-26694.r32">[32]</xref>&#x000a0;(Level IV). Similar results have been seen with pharmacist-managed anticoagulation compared to telephone/usual care clinics. AF management guidelines published by the European Society of Cardiology have stressed the importance of integrated management in coordinating care and improving outcomes.</p>
      </sec>
      <sec id="article-26694.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26694&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26694">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/paroxysmal-atrial-fibrillation/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26694">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26694/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26694">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26694.s15">
        <title>References</title>
        <ref id="article-26694.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ashurst</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <chapter-title>Supraventricular Tachycardia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">28723001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Tchou</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
            </person-group>
            <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Dec</month>
            <day>02</day>
            <volume>130</volume>
            <issue>23</issue>
            <fpage>2071</fpage>
            <page-range>2071-104</page-range>
            <pub-id pub-id-type="pmid">24682348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maisel</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Rawn</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>Atrial fibrillation after cardiac surgery.</article-title>
            <source>Ann Intern Med</source>
            <year>2001</year>
            <month>Dec</month>
            <day>18</day>
            <volume>135</volume>
            <issue>12</issue>
            <fpage>1061</fpage>
            <page-range>1061-73</page-range>
            <pub-id pub-id-type="pmid">11747385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chugh</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Havmoeller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narayanan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rienstra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Gillum</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>McAnulty</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Forouzanfar</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Naghavi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mensah</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Ezzati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Feb</month>
            <day>25</day>
            <volume>129</volume>
            <issue>8</issue>
            <fpage>837</fpage>
            <page-range>837-47</page-range>
            <pub-id pub-id-type="pmid">24345399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ball</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carrington</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century.</article-title>
            <source>Int J Cardiol</source>
            <year>2013</year>
            <month>Sep</month>
            <day>01</day>
            <volume>167</volume>
            <issue>5</issue>
            <fpage>1807</fpage>
            <page-range>1807-24</page-range>
            <pub-id pub-id-type="pmid">23380698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Go</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hylek</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Henault</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Selby</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.</article-title>
            <source>JAMA</source>
            <year>2001</year>
            <month>May</month>
            <day>09</day>
            <volume>285</volume>
            <issue>18</issue>
            <fpage>2370</fpage>
            <page-range>2370-5</page-range>
            <pub-id pub-id-type="pmid">11343485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nattel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dobrev</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities.</article-title>
            <source>Eur Heart J</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>15</issue>
            <fpage>1870</fpage>
            <page-range>1870-7</page-range>
            <pub-id pub-id-type="pmid">22507975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wakili</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Voigt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>K&#x000e4;&#x000e4;b</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dobrev</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nattel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in the molecular pathophysiology of atrial fibrillation.</article-title>
            <source>J Clin Invest</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>121</volume>
            <issue>8</issue>
            <fpage>2955</fpage>
            <page-range>2955-68</page-range>
            <pub-id pub-id-type="pmid">21804195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wijffels</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Dorland</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Allessie</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.</article-title>
            <source>Circulation</source>
            <year>1995</year>
            <month>Oct</month>
            <day>01</day>
            <volume>92</volume>
            <issue>7</issue>
            <fpage>1954</fpage>
            <page-range>1954-68</page-range>
            <pub-id pub-id-type="pmid">7671380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fareh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Nattel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.</article-title>
            <source>Circulation</source>
            <year>1999</year>
            <month>Jul</month>
            <day>06</day>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-95</page-range>
            <pub-id pub-id-type="pmid">10393686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nattel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation.</article-title>
            <source>Cardiovasc Res</source>
            <year>1999</year>
            <month>May</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>298</fpage>
            <page-range>298-308</page-range>
            <pub-id pub-id-type="pmid">10533568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Baranchuk</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ashman phenomenon dynamicity during atrial fibrillation: the critical role of the long cycles.</article-title>
            <source>J Atr Fibrillation</source>
            <year>2017</year>
            <season>Oct-Nov</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>1656</fpage>
            <pub-id pub-id-type="pmid">29250245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jauss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Veltkamp</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nabavi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weimar</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hrmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wachter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study.</article-title>
            <source>Stroke</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>12</issue>
            <fpage>3357</fpage>
            <page-range>3357-64</page-range>
            <pub-id pub-id-type="pmid">24130137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wyse</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Waldo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>DiMarco</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Domanski</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schron</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Kellen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Mickel</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Dalquist</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Corley</surname>
                <given-names>SD</given-names>
              </name>
              <collab>Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators</collab>
            </person-group>
            <article-title>A comparison of rate control and rhythm control in patients with atrial fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2002</year>
            <month>Dec</month>
            <day>05</day>
            <volume>347</volume>
            <issue>23</issue>
            <fpage>1825</fpage>
            <page-range>1825-33</page-range>
            <pub-id pub-id-type="pmid">12466506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saksena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Slee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waldo</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Freemantle</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Rathod</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wyse</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2011</year>
            <month>Nov</month>
            <day>01</day>
            <volume>58</volume>
            <issue>19</issue>
            <fpage>1975</fpage>
            <page-range>1975-85</page-range>
            <pub-id pub-id-type="pmid">22032709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagens</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Van Gelder</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Crijns</surname>
                <given-names>HJ</given-names>
              </name>
              <collab>RAte Control Versus Electrical Cardioversion Of Persistent Atrial Fibrillation (RACE) Study Group</collab>
            </person-group>
            <article-title>The RACE study in perspective of randomized studies on management of persistent atrial fibrillation.</article-title>
            <source>Card Electrophysiol Rev</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-21</page-range>
            <pub-id pub-id-type="pmid">14618033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rosenqvist</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.</article-title>
            <source>Eur Heart J</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>1500</fpage>
            <page-range>1500-10</page-range>
            <pub-id pub-id-type="pmid">22246443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Bridgers</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Carliner</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Colling</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Gornick</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Krause-Steinrauf</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kurtzke</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Nazarian</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Nov</month>
            <day>12</day>
            <volume>327</volume>
            <issue>20</issue>
            <fpage>1406</fpage>
            <page-range>1406-12</page-range>
            <pub-id pub-id-type="pmid">1406859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <article-title>Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.</article-title>
            <source>Arch Intern Med</source>
            <year>1994</year>
            <month>Jul</month>
            <day>11</day>
            <volume>154</volume>
            <issue>13</issue>
            <fpage>1449</fpage>
            <page-range>1449-57</page-range>
            <pub-id pub-id-type="pmid">8018000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hart</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Pearce</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.</article-title>
            <source>Ann Intern Med</source>
            <year>2007</year>
            <month>Jun</month>
            <day>19</day>
            <volume>146</volume>
            <issue>12</issue>
            <fpage>857</fpage>
            <page-range>857-67</page-range>
            <pub-id pub-id-type="pmid">17577005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connolly</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oldgren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pogue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Themeles</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Varrone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alings</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xavier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Darius</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Diener</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Joyner</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <collab>RE-LY Steering Committee and Investigators</collab>
            </person-group>
            <article-title>Dabigatran versus warfarin in patients with atrial fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Sep</month>
            <day>17</day>
            <volume>361</volume>
            <issue>12</issue>
            <fpage>1139</fpage>
            <page-range>1139-51</page-range>
            <pub-id pub-id-type="pmid">19717844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hacke</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Breithardt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hankey</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Piccini</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Paolini</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
              <collab>ROCKET AF Investigators</collab>
            </person-group>
            <article-title>Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Sep</month>
            <day>08</day>
            <volume>365</volume>
            <issue>10</issue>
            <fpage>883</fpage>
            <page-range>883-91</page-range>
            <pub-id pub-id-type="pmid">21830957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hylek</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Khalidi</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Ansell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Atar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Avezum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bahit</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Flaker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Geraldes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Golitsyn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hermosillo</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Hohnloser</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mohan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jansky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Lopez-Sendon</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pais</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verheugt</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <collab>ARISTOTLE Committees and Investigators</collab>
            </person-group>
            <article-title>Apixaban versus warfarin in patients with atrial fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Sep</month>
            <day>15</day>
            <volume>365</volume>
            <issue>11</issue>
            <fpage>981</fpage>
            <page-range>981-92</page-range>
            <pub-id pub-id-type="pmid">21870978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouida</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Beltaief</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Msolli</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Azaiez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ben Soltane</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sekma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trabelsi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Boubaker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grissa</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Methemem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boukef</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dridi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Belguith</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nouira</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid Atrial Fibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study).</article-title>
            <source>Acad Emerg Med</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-191</page-range>
            <pub-id pub-id-type="pmid">30025177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naccarelli</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Dell'Orfano</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Wolbrette</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Luck</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Cost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy.</article-title>
            <source>Am J Cardiol</source>
            <year>2000</year>
            <month>May</month>
            <day>25</day>
            <volume>85</volume>
            <issue>10A</issue>
            <fpage>36D</fpage>
            <page-range>36D-45D</page-range>
            <pub-id pub-id-type="pmid">10822039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elhendy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khandheria</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Hammill</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Seward</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Predictors of unsuccessful electrical cardioversion in atrial fibrillation.</article-title>
            <source>Am J Cardiol</source>
            <year>2002</year>
            <month>Jan</month>
            <day>01</day>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-6</page-range>
            <pub-id pub-id-type="pmid">11779532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cosedis Nielsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johannessen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Raatikainen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hindricks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Walfridsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kongstad</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pehrson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Englund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hartikainen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mortensen</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Oct</month>
            <day>25</day>
            <volume>367</volume>
            <issue>17</issue>
            <fpage>1587</fpage>
            <page-range>1587-95</page-range>
            <pub-id pub-id-type="pmid">23094720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caro</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation.</article-title>
            <source>Am J Manag Care</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>14 Suppl</issue>
            <fpage>S451</fpage>
            <page-range>S451-58; discussion S458-61</page-range>
            <pub-id pub-id-type="pmid">15696909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McManus</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Rienstra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>An update on the prognosis of patients with atrial fibrillation.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Sep</month>
            <day>04</day>
            <volume>126</volume>
            <issue>10</issue>
            <fpage>e143</fpage>
            <page-range>e143-6</page-range>
            <pub-id pub-id-type="pmid">22949543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Villani</surname>
                <given-names>GQ</given-names>
              </name>
              <name>
                <surname>Aschieri</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Risk of complications of atrial fibrillation.</article-title>
            <source>Pacing Clin Electrophysiol</source>
            <year>1997</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10 Pt 2</issue>
            <fpage>2684</fpage>
            <page-range>2684-91</page-range>
            <pub-id pub-id-type="pmid">9358515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hendriks</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>de Wit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Crijns</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Vrijhoef</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pisters</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pison</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Blaauw</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tieleman</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation.</article-title>
            <source>Eur Heart J</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>21</issue>
            <fpage>2692</fpage>
            <page-range>2692-9</page-range>
            <pub-id pub-id-type="pmid">22453654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26694.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frydensberg</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Brandes</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Does an interdisciplinary outpatient atrial fibrillation (AF) clinic affect the number of acute AF admissions? A retrospective cohort study.</article-title>
            <source>J Clin Nurs</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>13-14</issue>
            <fpage>2684</fpage>
            <page-range>2684-2690</page-range>
            <pub-id pub-id-type="pmid">29603828</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
